Update
$Caribou Biosciences(CRBU.US$ Caribou Biosciences (CRBU) said late Tuesday it has reached alignment with the US Food and Drug Administration with respect to the trial design of a planned phase 3 study of CB-010 for the treatment of patients with second-line relapsed or refractory large B cell lymphoma.
The regulator found a proposed comparator arm of platinum-based immunochemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation to be "acceptable," the company said.![]()
The regulator found a proposed comparator arm of platinum-based immunochemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation to be "acceptable," the company said.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
